CGS Stock Overview
A neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cogstate Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.98 |
| 52 Week High | AU$1.56 |
| 52 Week Low | AU$0.80 |
| Beta | 0.091 |
| 11 Month Change | 9.44% |
| 3 Month Change | -14.35% |
| 1 Year Change | -32.53% |
| 33 Year Change | -58.96% |
| 5 Year Change | 149.37% |
| Change since IPO | 392.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| CGS | AU Healthcare Services | AU Market | |
|---|---|---|---|
| 7D | 2.1% | 2.7% | -0.07% |
| 1Y | -32.5% | 121.0% | 16.9% |
Return vs Industry: CGS underperformed the Australian Healthcare Services industry which returned 121% over the past year.
Return vs Market: CGS underperformed the Australian Market which returned 16.9% over the past year.
Price Volatility
| CGS volatility | |
|---|---|
| CGS Average Weekly Movement | 7.0% |
| Healthcare Services Industry Average Movement | 8.2% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.0% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: CGS has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: CGS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 160 | Brad O'Connor | www.cogstate.com |
Cogstate Limited, a neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research. Its cognitive services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. The company is involved in the design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments.
Cogstate Limited Fundamentals Summary
| CGS fundamental statistics | |
|---|---|
| Market cap | AU$170.92m |
| Earnings (TTM) | AU$8.44m |
| Revenue (TTM) | AU$67.27m |
20.2x
P/E Ratio2.5x
P/S RatioIs CGS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGS income statement (TTM) | |
|---|---|
| Revenue | US$43.43m |
| Cost of Revenue | US$19.13m |
| Gross Profit | US$24.30m |
| Other Expenses | US$18.85m |
| Earnings | US$5.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.032 |
| Gross Margin | 55.96% |
| Net Profit Margin | 12.55% |
| Debt/Equity Ratio | 0.3% |
How did CGS perform over the long term?
See historical performance and comparison